Article
Author(s):
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A piece by Devex cited a study published in the February 2018 issue of The American Journal of Managed Care® (AJMC®), titled “Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?.” The study found that the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.
An article by Washington Examiner referenced a piece published on AJMC.com, the website of AJMC®. The piece, “Caution Strongly Recommended When Using Chloroquine, Hydroxychloroquine in Patients With Cardiovascular Disease, COVID-19,” indicated that despite positive results seen from the use of chloroquine and hydroxychloroquine in some patients hospitalized with coronavirus disease 2019 (COVID-19), concern is mounting about how these drugs affect patients’ cardiovascular health, specifically the heart.
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.